EEVIA Stock Overview
Produces and distributes organic bioactive plant extracts in Finland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Eevia Health Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.25 |
| 52 Week High | SEK 1.80 |
| 52 Week Low | SEK 0.13 |
| Beta | 1.15 |
| 11 Month Change | 24.50% |
| 3 Month Change | -50.98% |
| 1 Year Change | -79.76% |
| 33 Year Change | -97.51% |
| 5 Year Change | n/a |
| Change since IPO | -96.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| EEVIA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 27.7% | -5.5% | -2.4% |
| 1Y | -79.8% | 9.1% | 10.9% |
Return vs Industry: EEVIA underperformed the Swedish Pharmaceuticals industry which returned 8% over the past year.
Return vs Market: EEVIA underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| EEVIA volatility | |
|---|---|
| EEVIA Average Weekly Movement | 17.6% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: EEVIA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: EEVIA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 21 | Stein Ulve | eeviahealth.com |
Eevia Health Oyj produces and distributes organic bioactive plant extracts in Finland and internationally. The company offers bilberry, lingonberry, chaga-mushroom, pine bark, elderberry, and tart cherry extracts. Its products are used in dietary supplements and food products.
Eevia Health Oyj Fundamentals Summary
| EEVIA fundamental statistics | |
|---|---|
| Market cap | SEK 16.02m |
| Earnings (TTM) | -SEK 26.21m |
| Revenue (TTM) | SEK 23.13m |
0.7x
P/S Ratio-0.6x
P/E RatioIs EEVIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EEVIA income statement (TTM) | |
|---|---|
| Revenue | €1.99m |
| Cost of Revenue | €530.35k |
| Gross Profit | €1.46m |
| Other Expenses | €3.73m |
| Earnings | -€2.26m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 29, 2024
| Earnings per share (EPS) | -0.035 |
| Gross Margin | 73.41% |
| Net Profit Margin | -113.34% |
| Debt/Equity Ratio | 53.3% |
How did EEVIA perform over the long term?
See historical performance and comparison